<?xml version="1.0" encoding="UTF-8"?>
	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">
		
		<url>
			<loc>https://oncotarget.pro/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/about/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/farmakonadzor/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/career/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/manufacture/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/r-d-tsentr/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/quality/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/media/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/contacts/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/cookies/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/policy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/terms-of-use/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/about/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/farmakonadzor/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/career/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/manufacture/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/r-d-tsentr/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/quality/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/media/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/contacts/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/policy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/en/terms-of-use/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/ploshchadka-onkotarget-konsolidiruet-usiliya-po-vypusku-preparatov-naibolee-vostrebovannykh-nozologi2/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/sergey-sobyanin-posetil-proizvodstvennuyu-ploshchadku-onkotarget-dlya-obsuzhdeniya-mer-podderzhki-fa/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/predstaviteli-farmindustrii-o-merakh-podderzhki-otrasli-moskva-rabotaet-na-operezhenie-/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/vlasti-moskvy-rasskazali-o-podderzhke-stolichnoy-farmpromyshlennosti-v-usloviyakh-sanktsiy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/sergey-sobyanin-zayavil-o-neobkhodimosti-prinyatiya-mer-dlya-uskorennogo-importozameshcheniya-po-obe/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/farmotrasl-pri-podderzhke-vlastey-moskvy-gotova-k-importozameshcheniyu/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/na-ploshchadke-onkotarget-zapushcheno-proizvodstvo-pervogo-rossiyskogo-preparata-spasayushchego-ot-r/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/onkotarget-zapuskaet-proizvodstvo-pervogo-rossiyskogo-preparata-dlya-lecheniya-snizhennogo-polovogo-/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/kompaniya-onkotarget-pozdravlyaet-moskvichey-s-dnem-goroda/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/v-rossii-vpervye-razvernuto-proizvodstvo-dantrolena-preparata-kotoryy-snizhaet-smertnost-ot-zlokache/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/onkotarget-pervym-v-rocsii-zapustil-proizvodstvo-tofatsitiniba-na-osnove-sobstvennoy-substantsii/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/ispolnilsya-god-so-dnya-registratsii-v-rossii-preparata-dantrolen-spasayushchego-ot-zlokachestvennoy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/zaregistrirovan-preparat-dlya-terapii-khronicheskogo-mieloleykoza/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/vrachi-vpervye-spasli-rebenka-ot-zlokachestvennoy-gipertermii-s-pomoshchyu-rossiyskogo-preparata/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/importozameshchenie-v-kriticheskikh-oblastyakh-zaregistrirovan-rossiyskiy-preparat-dlya-lecheniya-kh/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/na-strazhe-suvereniteta-kak-moskovskaya-promyshlennost-zameshchaet-zarubezhnye-analogi/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/farma-2030-strategicheskie-resheniya-dlya-dostupnosti-lekarstv/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/neobkhodimo-vosstanavlivat-bazovuyu-khimiyu/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/v-rossii-zaregistrirovan-pervyy-otechestvennyy-analog-aksitiniba-preparata-dlya-lecheniya-raka-pochk/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/minzdrav-rf-zaregistriroval-pervyy-rossiyskiy-analog-aksitiniba/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/zaregistrirovan-pervyy-rossiyskiy-analog-ruksolitiniba-preparata-primenyaemogo-dlya-targetnoy-terapi/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/novye-rossiyskie-bioanalogi-i-dzheneriki-protiv-raka-zanyali-60-vsego-rynka-klinicheskikh-issledovan/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/novye-rossiyskie-dzheneriki-i-bioanalogi-protiv-raka-zanyali-60-vsego-rynka-klinicheskikh-issledovan/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/ekonomika-rossii-teryaet-milliardy-iz-za-vliyaniya-raka-na-trudovye-resursy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/bolee-100-predstaviteley-tekhnoparkov-rf-i-oez-posetili-tekhnopolis-moskvu/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/v-oez-tekhnopolis-moskva-gotovyatsya-k-novomu-godu/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/kompaniya-onkotarget-pozdravlyaet-prekrasnykh-dam-s-8-marta/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/onkotarget-i-drugie-rezidenty-oez-tekhnopolis-moskva-pozdravili-veteranov-s-dnem-pobedy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/pozdravlyaem-s-dnyem-khimika-prazdnikom-tekh-kto-sozdayet-zdorove/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/na-strazhe-zdorovya-pozdravlyaem-s-dnem-farmatsevticheskogo-rabotnika/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/zdorove-natsii-v-vashikh-rukakh-chestvuem-geroev-meditsiny/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/federalnaya-sluzhba-po-nadzoru-v-sfere-zashchity-prav-potrebiteley-i-blagopoluchiya-cheloveka-provel/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/v-tekhnopolise-moskva-sostoyalas-rabochaya-vstrecha-delegatsii-ministerstva-truda-i-sotsialnykh-vopr/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/kompaniya-onkotarget-voshla-v-reyting-rossiyskikh-farmproizvoditeley-polnogo-tsikla-/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/kompaniya-onkotarget-prinyala-uchastie-v-yarmarke-vakansiy-oez-tekhnopolis-moskva-i-predstavila-svoi/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/news/sotrudnik-kompanii-onkotarget-otmechen-blagodarnostyu-na-torzhestvennom-meropriyatii-v-ramkakh-mesya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/endokrinologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/kardiologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/ginekologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/dermatologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/intensivnaya-terapiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/gastroenterologiya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/sunitinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/dazatinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/temozolomid/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/gemtsitabin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/gefitinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/dotsetaksel/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/sorafenib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/fulvestrant/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/bozutinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/osimertinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/aksitinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/ruksolitinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/kabazitaksel/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/afatinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/lenvatinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/lapatinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/onkologiya-onkogematologiya/trastuzumab/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/endokrinologiya/tsinakaltset/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/endokrinologiya/vildagliptin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/kardiologiya/apiksaban/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/ginekologiya/dizayriks/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/intensivnaya-terapiya/anidulafungin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/intensivnaya-terapiya/deksmedetomidin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/intensivnaya-terapiya/dantrolen/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/intensivnaya-terapiya/tigetsiklin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/gastroenterologiya/infliksimab/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/nitizinon/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/gadodiamid/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/teriflunomid/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/tofatsitinib/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/ibandronovaya-kislota/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/gadopentetovaya-kislota/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/epostim/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/leytragin/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/catalog/inye-napravleniya/asprovit-s/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/vozmozhnosti-primeneniya-sunitiniba-pri-neyroendokrinnykh-opukholyakh-podzheludochnoy-zhelezy-1/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/sunitinib-pri-neyroendokrinnykh-opukholyakh-podzheludochnoy-zhelezy-klinicheskiy-sluchay/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/sunitinib-v-terapii-metastaticheskogo-pochechno-kletochnogo-raka/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/metastaticheskiy-pochechno-kletochnyy-rak-vozmozhnosti-targetnoy-terapii/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/ostalos-li-mesto-sunitinibu-v-sovremennykh-rekomendatsiyakh-po-sistemnomu-lecheniyu-rasprostranennog/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/reaktualizatsiya-sunitiniba-v-terapii-metastaticheskogo-pochechno-kletochnogo-raka/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/effektivnost-ingibitora-tirozinkinaz-1-go-pokoleniya-sunitinib-v-terapii-metastaticheskogo-pochechno/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/sunitinib-v-terapii-metastaticheskogo-pochechno-kletochnogo-raka-1/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/mesto-fulvestranta-v-lechenii-bolnykh-metastaticheskim-lyuminalnym-her2-negativnym-rakom-molochnoy-zh/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/tofatsitinib-v-lechenii-revmatoidnogo-artrita-dannye-realnoy-praktiki-i-randomizirovannykh-kliniches/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/effektivnost-tofatsitiniba-pri-psoriaticheskom-artrite-obzor-literatury-i-klinicheskoe-nablyudenie/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/25-letniy-opyt-lecheniya-khronicheskogo-mieloleykoza-ingibitorami-tirozinkinaz-rezultaty-vozmozhnost/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/mesto-tirozinkinaznykh-ingibitorov-v-pervoy-linii-lecheniya-gepatotsellyulyarnoy-kartsinomy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/lechenie-metastaticheskogo-svetlokletochnogo-raka-pochki-fokus-na-patsientakh-blagopriyatnoy-prognos/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/aktualnye-voprosy-terapii-patsientov-s-yazvennym-kolitom/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/sobstvennyy-opyt-primeneniya-kombinirovannoy-terapii-v-pervoy-linii-lecheniya-metastaticheskogo-svet/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/ingibitory-tirozinkinaz-vtorogo-pokoleniya-pri-khronicheskom-mieloidnom-leykoze-segodnya-effektivnos/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/primenenie-tofatsitiniba-pri-psoriaticheskom-artrite-obzor-literatury/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/primenenie-tofatsitiniba-v-lechenii-yazvennogo-kolita-realnaya-klinicheskaya-praktika-i-perspektivy/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/tofatsitinib-kak-sredstvo-optimizatsii-lecheniya-revmatoidnogo-artrita-na-ambulatornom-etape-klinich/</loc>
			<priority>1</priority>
		</url>
		
		<url>
			<loc>https://oncotarget.pro/scientific-publications/peroralnyy-glyukozotolerantnyy-test-vo-vremya-beremennosti-voprosy-i-otvety/</loc>
			<priority>1</priority>
		</url>
		
	</urlset>
	